Managers from Cytiva and Pall, which are part of Danaher, said they will expand manufacturing capacity and services across geographies for global life science customers. A $ 1.5 billion, two-year investment already underway includes new sites, expansion of existing plants and builds on previously announced investments. It follows five acquisitions made by the companies so far this year.
“Our customers tell us they need access to manufacturing agility, a robust global supply chain and more regional options,” said Emmanuel Ligner, director of the Danaher group. “This investment further fuels our expansion program so that we can respond quickly to the current and future needs of our customers and ultimately their patients.” “
The expansion of Cytiva and Pall’s capabilities will increase the manufacturing of key products used to make biologic drugs, Ligner added. The companies invest more than $ 600 million in chromatography resins and establish a new manufacturing site in the United States, more than $ 400 million in cell culture media and expand their operations in the United States, UK United States and Austria, more than $ 300 million in single-use technologies, and expansion of operations in the United States and United Kingdom, as well as the development of a new facility in Cardiff, Country of Wales, and over $ 200 million for continued expansion work at the Cytiva and Pall sites in China and the rest of the Asia-Pacific region, Europe and the United States.
This investment also addresses some of the key challenges highlighted in the Global Biopharma Resilience Index, conducted by Longitude, a Financial Times company, and published by Cytiva in March. These include hiring and training talent, R&D collaboration, supply chain resilience, manufacturing models, and government policies and regulations.
Rapid expansion program
Funds will be allocated immediately to accelerate capacity expansion plans already underway at 13 Pall and Cytiva sites manufacturing biotech products for COVID-19 and other critical programs. For example, the production of cell culture media at the Cytiva site in Logan, UT, is expected to double in 2023. This will be done by converting 25,000 m2 of land in new manufacturing lines, distribution centers and clean rooms, as well as the creation of 250 new jobs locally. Combined with the acquisition of Intermountain Life Sciences by Cytiva in June, a manufacturer of liquid cell culture media and buffers, customers supplied by Logan will see shorter lead times in the delivery of these products, according to a carrier. word of Danaher.
The $ 1.5 billion investment follows Cytiva’s 2020 announcement to spend $ 500 million to build capacity. The investment has already funded a new manufacturing facility in Shrewsbury, MA, and a new cleanroom in Westborough, MA. A new cell and gene therapy manufacturing site and a center of excellence should open in Switzerland in 2022.
As part of the announced investment, Pall will expand its single-use manufacturing operations in China at the recently acquired Austar site. Plans are also underway to expand Cytiva’s partnership with Wego in China to strengthen single-use technology manufacturing capacity for the region. The two companies are planning further regional investments in the future.
A new 11,000 m2 The plant in Cardiff, Wales, is being upgraded to manufacture single-use bioprocessing equipment, including connector tube sets, cell bags and ÄKTA flow kits. The first products are expected to be manufactured at this site before the end of 2021. A local hiring campaign has started to fill 250 new jobs over the next two years, mainly in manufacturing, as well as warehouse operators, material handlers and scientists in R&D. .
The vision for the new US plant is to replicate and complement Cytiva’s resin manufacturing capabilities at its site in Uppsala, Sweden, a Cytiva official said. The location of the new site will be announced at a later date. Cytiva plans to hire 400 people in the United States and Sweden over the next two years to facilitate expansion plans.
Overall, the companies plan to hire 2,000 people over the next two years to support growth. This is in addition to the 2,000 new associates hired by Cytiva and Pall over the past year. The approach takes into account the well-established skills gap in the biotechnology industry. For example, training for manufacturing roles will involve intensive on-site courses. Integration for highly technical roles will take advantage of Cytiva’s FastTrak centers and online training designed in partnership with the National Institute for Bioprocessing Research and Training (NIBRT) in Dublin, Ireland.
Supporting the biotechnology industry through rapid growth requires access to innovative technologies as well as manufacturing capacity.
“We envision a world in which access to life-changing therapies transforms human health. Our investments and acquisitions are aimed at strengthening the therapeutic development capacity and workflow to advance and accelerate the work of our clients, ”said Ligner.
Recent acquisitions by Pall and Cytiva include:
- Vanrx Pharmasystems, Canada (acquired by Cytiva in February 2021) Aseptic pharmaceutical filling solutions that automate the preparation of small batches of biological drugs, well suited for the manufacture of cell and gene therapy.
- Austar, China (acquired by Pall in March 2021) Additional single-use technology manufacturing capabilities in China to help meet regional vaccine manufacturing needs, driven by COVID-19.
- GoSilico, Germany (acquired by Cytiva in June 2021) Mechanistic modeling software to create ‘digital twin’ simulations of downstream bioprocessing steps for more efficient chromatography and drug manufacturing process development.
- Precision NanoSystems, Canada (acquired by Pall in June 2021) Manufacture and development of lipid nanoparticles for the delivery of genetic drugs, including mRNA vaccines and therapeutics.
- The previously mentioned acquisition of Intermountain Life Sciences by Cytiva.